Octasa is commonly used in situations involving certain distressing symptoms related to the colon. It is applied across therapeutic domains where additional symptomatic support is needed for managing inflammatory processes in the gastrointestinal tract.

This medication is commonly used to help manage mild-to-moderate active phases of Ulcerative Colitis (UC), a chronic form of Inflammatory Bowel Disease (IBD). Its uses are relevant to supporting the goal of achieving clinical remission, managing the risk of future disease relapses, and addressing inflammation localized in the lower bowel, such as ulcerative proctitis and distal colitis.

The treatment is focused on managing the underlying inflammation, which may help support the process of inducing clinical remission. By managing the inflammation, Octasa helps address symptom clusters that may become intense or disruptive, such as severe abdominal cramping and bloody stools. This continuous use may contribute to improved comfort and helps ease the overall symptom burden.

---

Quick Fact: Supportive Management for Symptoms of Inflammation Octasa is applied across conditions marked by increased discomfort and is typically used when the symptom clusters are related to inflammatory or irritative processes in the colon lining.

This information details the officially documented criteria for who may and may not use Octasa, based on regulatory labeling.

Contraindicated Populations

Octasa is contraindicated and must not be used by patients who have known hypersensitivity to mesalazine (the active ingredient), any other components of the tablet, or any salicylates (such as aspirin). Use is also prohibited in patients with severe renal impairment (specifically, a Glomerular Filtration Rate (GFR) less than 30 mL/min/1.73 m^2) and in those with severe hepatic impairment.

Age and Physical Restrictions

Population	Eligibility Status (Tablet Strengths)
Children 6 years and older	Approved for use (400 mg and 800 mg tablets only).
Children under 6 years	Not recommended; safety and efficacy are not established.
Patients unable to swallow	Contraindicated, as the tablet must be swallowed whole to function correctly.

Special Considerations for Use

Patients with existing gastric or duodenal ulcers, mild-to-moderate renal or hepatic function impairment, and those with a history of cardiac hypersensitivity reactions (myocarditis/pericarditis) to mesalazine or similar drugs should use Octasa only with extreme caution and close medical monitoring. The prescribing information states that patients with urinary tract obstruction should also not use this medicine. During pregnancy and lactation, the medicine should only be used if the potential benefit is judged to outweigh the possible risk.

Octasa (mesalazine) may interact with a number of other medications. It is important to inform your doctor or pharmacist of all prescription and non-prescription drugs, vitamins, supplements, and herbal remedies you are currently taking, as this information is essential for ensuring your safety and the effectiveness of your treatment.

Drug-Drug Interactions

The following table lists certain drug classes that may interact with Octasa. This is not a complete list, and your healthcare provider can provide comprehensive guidance.

Drug Class	Potential Interaction
Immunosuppressants	Octasa may increase the risk of side effects from medicines such as azathioprine or 6-mercaptopurine by altering their metabolism, which could lead to an increased risk of blood disorders.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)	Combining Octasa with NSAIDs like ibuprofen or aspirin may increase the risk of side effects, particularly those affecting the kidneys.
Anticoagulants	Octasa may weaken the effects of blood-thinning medicines, such as warfarin, making them less effective at preventing blood clots, though evidence is weak.

Close monitoring of your blood tests, including kidney function, is typically required when Octasa is used concurrently with immunosuppressants or NSAIDs. Additionally, stay well-hydrated during treatment with Octasa to help minimize the risk of kidney-related side effects, particularly when taking other interacting medications.

The mechanism of Octasa (Mesalazine) is defined by its localized, multi-targeted action on cellular events that mediate inflammation within the intestinal lining. It achieves its effect through the simultaneous modulation of several key biological domains.

Modulation of Inflammatory Gene Expression

This domain covers the drug's action on nuclear targets, primarily the inhibition of NF-kappa B (Nuclear Factor-kappa B) and the activation of PPAR-gamma (Peroxisome Proliferator-Activated Receptor gamma). By directly influencing these factors, Mesalazine suppresses the underlying gene transcription responsible for generating pro-inflammatory mediators like cytokines ( TNF-alpha). This molecular control modulates the signaling responsible for sustained local immune response activity.

Suppression of Eicosanoid Pathways

This mechanism focuses on enzyme inhibition within the Arachidonic Acid Cascade. Mesalazine inhibits the enzyme COX-2 (Cyclooxygenase-2), which is critical for producing inflammatory signaling molecules known as prostaglandins. The resulting physiological effect is a reduction in localized vascular permeability and resulting perivascular fluid shifts.

Cellular Protection via Antioxidant Scavenging

Mesalazine functions as a direct scavenger of Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS). These free radicals are released by active inflammatory cells and cause severe oxidative stress and damage to the mucosal lining. By neutralizing these reactive molecules, the drug influences the structural integrity of the intestinal tissue, reducing the potential for cellular injury that sustains the inflammatory response.

How to Use Octasa (Mesalazine) — Administration Guidelines

Octasa (mesalazine) is an oral modified-release tablet prescribed according to specific regimens for adults and children. Adherence to the administration steps is critical because the tablet's special coating is designed to release the active ingredient in the lower gastrointestinal tract.

Administration and Handling

• Method: The modified-release tablets must be swallowed whole with some liquid. They must not be chewed, crushed, or broken before swallowing.
• Timing: Doses should be taken preferably before food intake.
• Hydration: Patients are advised to ensure adequate fluid intake during treatment, particularly after episodes of high fluid loss, such as severe diarrhea or vomiting.

Standard Dosing Regimens (Adults)

Dosing is determined by the treatment phase and may be taken once daily or in divided doses, though higher daily doses must be divided:

Regimen	Daily Dose (Octasa 800 mg equivalent)
Acute Exacerbation	2.4 g to 4.8 g per day (3 to 6 tablets)
Maintenance of Remission	1.6 g to 2.4 g per day (2 to 3 tablets)

The maximum single dose should not exceed 2.4 g (three 800 mg tablets) at any one time. Doses above 2.4 g per day for acute disease must be taken in divided doses.

Population-Specific Rules

• Pediatric Patients (6+ years): Dosing is determined individually based on body weight (mg/kg/day), not to exceed adult maximums.
• Elderly Patients: The normal adult dosage is generally used unless there is severe impairment of liver or renal function.

Missed Dose

If one or more doses are missed, the next scheduled dose should be taken as usual. Do not take a double dose to compensate for a forgotten one.

Research Evidence / Overview of Studies for Octasa

Evidence for Inducing Remission in Mild-to-Moderate Ulcerative Colitis (UC)

The evidence base for mesalazine, the active component in Octasa, comes primarily from short-term randomized controlled trials (RCTs). These studies were used in research exploring how to approach periods of heightened symptom activity in adults with mild-to-moderate UC. Researchers focused on outcomes related to symptom control status and endoscopic remission (healing status of the colon lining).

The findings from these trials describe consistent patterns in measured outcomes related to the status of symptom control when compared to control groups. What remains uncertain is how the specific delivery system of Octasa compares directly against all other modified-release mesalazine brands, as comparative evidence is lacking from head-to-head trials.

Evidence for Maintaining Remission in Quiescent Ulcerative Colitis

Research shifted to long-term RCTs to explore patterns related to keeping the condition stable and preventing relapse. Studies monitored patients over extended observation periods, often between 6 and 12 months or longer, describing patterns related to the time to relapse.

Findings indicate that continued administration was associated with sustained measurements of non-active disease. This evidence contributes to understanding patterns related to the maintenance of low inflammatory markers. However, long-term effects are not fully established regarding adherence outside of trials, and data for therapy duration are still emerging.

Research on Localized Disease: Distal Colitis and Proctitis

Research also explored approaches for localized inflammation confined to the lower part of the bowel. Studies examined the use of oral formulations, often in comparison with or in combination with topical delivery methods. Findings describe patterns across measurements of localized inflammation with various delivery methods observed in some studies. Comparative evidence remains insufficient for relying solely on the oral, modified-release formulation to manage only the most distal segments.

Gaps, Limitations, and Areas of Uncertainty in the Research

The overall research landscape still contains defined gaps. Follow-up durations were limited in many initial short-term induction trials. Subgroup findings are uncertain for specific populations, such as older adults or those with significant comorbidities, as these groups were often underrepresented. The research provides context but not individual predictions; the evidence highlights what is known—and what is still uncertain—about group patterns.

Key Studies & References

1. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
2. What is the real-life maintenance mesalazine dose in ulcerative colitis? (Observational Study on Adherence and Dosing)
3. PUBLIC ASSESSMENT REPORT of the Medicines Evaluation Board in the Netherlands (Mesalazine Formulations)

Common questions about Octasa (FAQ)

---

Q: What is Octasa used for?

According to official product information, Octasa is used to treat ulcerative colitis, which is a condition causing inflammation and sores in the lining of the large intestine (colon and rectum). It is specifically used for mild to moderate active ulcerative colitis and to help prevent flare-ups (maintenance) of the condition. The active ingredient in Octasa is mesalazine (also known as 5-aminosalicylic acid or 5-ASA), which works locally in the bowel.

---

Q: Is Octasa a steroid or an immunosuppressant?

Octasa is neither a steroid nor a conventional immunosuppressant. It belongs to a group of medicines called aminosalicylates, which contain the active ingredient mesalazine. Official product information states that mesalazine works mainly by acting directly in the lining of the bowel to reduce inflammation. It is generally considered an anti-inflammatory agent for the bowel.

---

Q: How long do I need to take Octasa before seeing an effect?

Regulatory documents state that it may take some time before the full benefit of Octasa is noticed. The duration of treatment for an acute episode of ulcerative colitis is decided by a healthcare professional based on the individual's needs. Maintenance therapy is generally continued long-term as directed by the treating physician to help prevent flare-ups.

---

Q: Can I take Octasa if I am pregnant or breastfeeding?

Studies and official information indicate that mesalazine (the active ingredient in Octasa) should be used with caution during pregnancy and breastfeeding. It is known that mesalazine can cross the placenta and pass into breast milk in small amounts. Regulatory information advises that Octasa should only be used during these periods if a physician determines the potential benefits justify the potential risks to the fetus or infant.

---

Q: What should I do if I forget to take a dose of Octasa?

Official documentation advises that a missed dose may be taken as soon as the person remembers. If it is nearly time for the next dose, the person is instructed to skip the forgotten dose. The regular dosing schedule should then be resumed, and official guidance strictly advises against taking a double dose to compensate for the missed one.

---

Q: Can Octasa affect my kidneys or liver?

Official product information advises that Octasa should be used with caution in patients with impaired kidney or liver function. Regulatory documents recommend that blood tests to check your kidney function should be carried out before and during treatment, especially at the start. If a person has existing issues with these organs, regulatory documents state that treatment requires careful medical supervision.

How to Store and Dispose of Octasa?

Octasa (mesalazine) tablets and suppositories should be stored correctly to maintain their effectiveness.

Storage Instructions:

• Keep the medication at room temperature, typically between 59 F and 77 F (15 C and 25 C).
• Store Octasa away from moisture and excessive heat, such as bathrooms or near a stove.
• Keep the tablets and suppositories in their original container, tightly closed, and out of the sight and reach of children and pets.

Disposal Instructions:

• Do not dispose of Octasa by flushing it down a toilet or pouring it into a drain, unless specifically instructed by a healthcare professional.
• The safest method is to use a community drug take-back program or consult your pharmacist for guidance on proper disposal of unused or expired medication.
• Before discarding in household trash, mix the medication with an unappealing substance like dirt or used coffee grounds, place it in a sealed bag, and then dispose of it.